FAMILIARIZATION PROGRAMMES TO INDEPENDENT DIRECTORS

1. Objective

Suven Pharmaceuticals Ltd (Suven Pharma) endeavors to organize various programmes providing insights into the Company’s business operations to enable the Independent Directors understand Suven Pharma’s business models in depth and contribute significantly to the Company.

2. Familiarization Process

2.1. Suven Pharma shall through its Executive Directors / Key Managerial Personnel conduct programs / presentations periodically to familiarize the Independent Directors with the business models, operations, regulatory updates, functions of the Company and their roles, rights and responsibilities;

2.2. Such programs / presentations will provide an opportunity to the Independent Directors to interact with the senior management team of the Company and help them understand the business model of the Company, operations, service and product offerings, markets, organization structure, finance, human resources, technology, quality, facilities and risk management and such other areas as may arise from time to time;

2.3. The Company may circulate news and articles related to the industry on a regular basis and may provide specific regulatory/business activity updates from time to time; and

2.4. The Company may conduct an introductory familiarization program / presentation, when a new Independent Director comes on the Board of the Company.

2.5. The details of Programs shall be uploaded on the Company’s website for public information and a web link for the same shall also be provided in the Annual Report of the Company.

***
Programme Title: Familiarization Programs to Independent Directors

Date: 30th March, 2020: The Company organized Familiarization programmes on 1. Registration of Independent Directors and Online Proficiency Self-Assessment Test, 2. Significance of Role and Functioning of Independent Directors. Spent 1 hour on these programs by the following Independent Directors

Shri D.G. Prasad, Dr. Srivari Chandrasekhar and Smt. Deepanwita Chattopadhyay.